Elevation Wealth Partners’s Aligos Therapeutics ALGS Stock Holding History

Elevation Wealth Partners’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24	Hold	4	–	–	﹤0.01%	1301
2026 Q1	$30	Hold	4	–	–	﹤0.01%	1069
2025 Q4	$38	Hold	4	–	–	﹤0.01%	948
2025 Q3	$40	Hold	4	–	–	﹤0.01%	860
2025 Q2	$29	Hold	4	–	–	﹤0.01%	470
2025 Q1	$33	Hold	4	–	–	﹤0.01%	479
2024 Q4	$160	Hold	4	–	–	﹤0.01%	471
2024 Q3	$35	Hold	4	–	–	﹤0.01%	462
2024 Q2	$35	Hold	4	–	–	﹤0.01%	494
2024 Q1	$98	Hold	4	–	–	﹤0.01%	452
2023 Q4	$75	Hold	4	–	–	﹤0.01%	422
2023 Q3	$75	Hold	4	–	–	﹤0.01%	321
2023 Q2	$98	Hold	4	–	–	﹤0.01%	332
2023 Q1	$88	Buy	+4	New	+$153	﹤0.01%	333

Other funds holding ALGS

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Elevation Wealth Partners's ALGS Position: Q2 2026 in Review

Elevation Wealth Partners held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 4 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

Elevation Wealth Partners first reported a position in ALGS in Q1 2023 and has held it in 14 quarters since. The position peaked at $160 in Q4 2024. 3 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Elevation Wealth Partners held 4 shares of Aligos Therapeutics worth $24 as of Q2 2026.
Elevation Wealth Partners left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #1301 holding.
Elevation Wealth Partners first reported a position in Aligos Therapeutics in Q1 2023 and has held it in 14 quarters since.
Elevation Wealth Partners's Aligos Therapeutics position peaked at $160 in Q4 2024.
3 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.